320 replies to this topic

[ImmInst]

Geron and MannKind Brace for Increased FDA Scrutiny
Marketwire - 1 hour ago

NEW YORK, NY--(Marketwire - March 14, 2011) - There is plenty of optimism surrounding the Biotech industry as firmer pricing and new products have improved sales and earnings trends. Meanwhile ...

View the full article

[ImmInst]

GERON DOWNWARD MOMENTUM LOOKS TO CONTINUE (GERN)
Zacks.com - 21 hours ago

Mar 15, 2011 (SmarTrend® Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Geron (NASDAQ:GERN) on December 08, 2010 at $4.96. In approximately 3 months since that trend was ...

View the full article

[ImmInst]

Provectus (OTCBB: PVCT) Reports on Second End-of-Phase 2 Meeting with FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma
BiotechStockTrader.com - 30 minutes ago

By Justin Kuepper on Tuesday, March 22nd, 2011 Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a biopharmaceutical company focused on developing treatments for cancer and psoriasis based on the ...

View the full article

[ImmInst]

DOWNTREND SPOTTED IN SHARES OF GERON (GERN)
Zacks.com - 19 hours ago

Mar 22, 2011 (SmarTrend® Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Geron (NASDAQ:GERN) on December 08, 2010 at $4.96. In approximately 3 months, Geron has returned 3.3% as of ...

(via COMTEX News Network)-- - Benzinga

View the full article

[ImmInst]

Geron To Webcast Analyst And Investor Meeting On Company’s Oncology Programs On March 29, 2011
TheStreet.com - 1 hour ago

By Business Wire 03/24/11 - 08:30 AM EDT Geron Corporation (NASDAQ:GERN) today announced that it will host a live webcast of the analyst and investor meeting on its oncology programs being held in ...

GERON : to Webcast Analyst and Investor Meeting on Company's Oncology Programs on March 29, 2011 - 4-traders
Geron to Webcast Analyst and Investor Meeting on Company’s Oncology Programs on March 29, 2011 - SunHerald.com
PharmiWeb.com

View the full article

[ImmInst]

Lawyer lists Dobbs Ferry 4BD
Blockshopper - 1 hour ago

by Shania Sampson, published March 25, 2011 Yann Geron has listed for sale a four-bedroom, 4.5-bath home at 310 Palisade Ave. in Dobbs Ferry for $1.045 million. The 3,128-square-foot house was ...

View the full article

[ImmInst]

Needham & Company Maintains a 'Hold' on Geron Corporation (GERN); Lunch and a Solid Plan for Geron's Cancer Programs Were Served at the Investor/Analyst Meeting
StreetInsider.com - 1 hour ago

Needham analyst says, "We maintain our Hold rating, given the company technology value of ~$400MM and lack of sentinel events over the next 6-12 months to potentially drive GERN stock valuation ...

View the full article

[ImmInst]

BioWatch: Biotechs With 50% Implied Upside (GENZ, CEPH, ALNY, DNDN, GERN, HALO, VVUS)
24/7 Wall St. - 2 hours ago

Biotech is about to become even less and less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ) and Cephalon Inc. (NASDAQ: CEPH) will end up accounting ...

View the full article

[ImmInst]

Geron Co. (GERN) Given "Neutral" Rating by Zacks Investment Research Analysts
American Banking News - 2 hours ago

Equities research analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Geron Co. (NASDAQ: GERN) in a research note to investors on Thursday. The analysts currently have ...

View the full article

[ImmInst]

Geron To Webcast Analyst And Investor Meeting On Company’s Cell Therapy Programs On April 19, 2011
TheStreet.com - 1 hour ago

By Business Wire 04/14/11 - 08:30 AM EDT Geron Corporation (NASDAQ:GERN) today announced that it will host a live webcast of the analyst and investor meeting on its cell therapy programs being ...

Geron to Webcast Analyst and Investor Meeting on Company’s Cell Therapy Programs on April 19, 2011 - Business Wire
Geron to Webcast Analyst and Investor Meeting on Company’s Cell Therapy Programs on April 19, 2011 - PharmiWeb.com
SunHerald.com

View the full article

[ImmInst]

Geron Announces the Appointment of Melanie Nallicheri as Senior Vice President of Corporate Development for Cell Therapies
Business Wire - 1 hour ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the appointment of Melanie I. Nallicheri as Senior Vice President, Corporate Development, Cell Therapies. In ...

View the full article

[ImmInst]

Geron Announces Conference Call to Discuss First Quarter Financial Results and Highlights
Business Wire - 2 hours ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the closing ...

View the full article

[ImmInst]

Geron Q1 loss widens to $24.4M
San Jose Business Journal - 14 minutes ago

Geron Corp. on Wednesday reported a first quarter loss of $24.4 million, or 20 cents a share, widened from a loss in the same period last year of $16.6 million, or 18 cents a share. Menlo Park ...

View the full article

[ImmInst]

Geron Corporation Reports 2011 First Quarter Financial Results And Highlights
TheStreet.com - 27 minutes ago

By Business Wire 04/27/11 - 04:30 PM EDT For the first quarter of 2011, the company reported operating revenues of $1.5 million and operating expenses of $25.9 million, compared to $918,000 and ...

View the full article

[ImmInst]

Geron Co. (GERN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
American Banking News - 21 minutes ago

Geron Co. (GERN) announced its quarterly results on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.01 ...

View the full article

[ImmInst]

Stem Cell Stocks on the Upswing as Outlook Brightens
Marketwire - 48 minutes ago

NEW YORK, NY--(Marketwire - May 2, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger ...

View the full article

[ImmInst]

Geron Posts Wider Loss
Zacks.com - 23 minutes ago

Geron Corporation (GERN - Analyst Report) posted a net loss of 20 cents per share in the first quarter of 2011, wider than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss ...

View the full article

[ImmInst]

Stem-Cell Researchers Gain On US Court Decision
Wall Street Journal - 8 hours ago

Shares of several stem-cell-research groups were on a roll early Monday in the wake of a US appeals court decision Friday that will allow researchers who experiment with human embryonic stem cells ...

Select Stem Cell Stocks Surge After Favorable Court Ruling (PSTI, STEM, ATHX, ASTM, GERN, CUR, NBS, OSIR) - tickerspy Newswire

View the full article

[ImmInst]

Seeking to slow cash burn, StemCells lays off 20 people
San Francisco Business Times - 3 hours ago

StemCells Inc. will cut 30 percent of its workforce — about 20 full-time people — as it tries to advance its neural stem cell treatment through trials in spinal cord injury and a number of other ...

View the full article

[ImmInst]

Geron Gets $25M from California's Stem Cell Agency to Support Phase I hESC Therapy
Genetic Engineering News - 21 hours ago

Geron will receive a $25 million loan from the California Institute for Regenerative Medicine (CIRM) to support clinical development of it's Phase I human embryonic stem cell (hESC)-based ...

View the full article

[ImmInst]

EPO Ruling Confirms KAEL-GemVax's Patent Position on GV-1001
PharmiWeb.com - 23 minutes ago

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European ...

EPO Ruling Confirms KAEL-GemVax’s Patent Position on GV-1001 - SunHerald.com

View the full article

[ImmInst]

California Institute for Regenerative Medicine awards $25 mn for Geron's embryonic stem cell trial
pharmabiz.com - 48 minutes ago

Geron Corporation announced that the company has been approved to receive a Targeted Clinical Development Award totalling $25 million from the California Institute for Regenerative Medicine (CIRM ...

View the full article

[ImmInst]

KAEL-GemVax wins European telomerase patent challenge
News-Medical.net - 59 minutes ago

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European ...

View the full article

[ImmInst]

Geron spinal cord stem cell trial enrolls 2nd patient
Bizjournals.com - 1 hour ago

The study is focused on patients with fresh spinal cord injuries, as opposed to a trial by Palo Alto's StemCells Inc. (NASDAQ: STEM) that looks to treat patients with “chronic” spinal cord ...

View the full article

[ImmInst]

Nation's Second Participant Enrolls in Human Embryonic Stem Cell Trial
PR Newswire - 3 hours ago

CHICAGO, May 10, 2011 /PRNewswire-USNewswire/ -- Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC ...

Http://www.nmh.org/nm/home (Graphic: Business Wire) - TheStreet.com
Nation’s Second Participant Enrolls in Human Embryonic Stem Cell Trial - Centre Daily Times

View the full article

[ImmInst]

Beauty & the Beast of Stem Cell medicine. Xcell Clinic is shutdown, Advanced Cell Technology Shines
PR-USA.net - 33 minutes ago

The world is watching with eager anticipation two cutting edge US companies. Advanced Cell Technology (OTC:ACTC) and Geron Corporation (NASDAQ:GERN). Both companies are conducting US Food and Drug ...

View the full article

[ImmInst]

Stem Cell Research: Effects of the Patenting Landscape
Triple Helix Online - 2 hours ago

Ever since stem cell research began in the late 1900's, the field has been fraught with a variety of issues including bioethics, funding, and general skepticism. The debate on stem cells has been ...

View the full article

[ImmInst]

Investor Stem Cell prepares for Investor deluge: Increases Coverage of Stem Cell Companies:
PR-USA.net - 17 minutes ago

Investor Stem Cell announced today that it would increase coverage of the following companies in the regenerative medicine sector: Advanced Cell Technology (OTC:ACTC), Geron Corporation (NASDAQ ...

View the full article

[ImmInst]

EPO Ruling Confirms KAEL-GemVax's Patent Position on GV-1001
PharmaLive.com - 1 hour ago

SEOUL, South Korea & OSLO, Norway--(BUSINESS WIRE)--May 9, 2011 - KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office ...

View the full article

[ImmInst]

Investor Stem Cell Declares 2011 Stem Cell Leaders
Online PR News - 1 hour ago

This year's principal leaders in the sector are as follows: Geron Corporation (NASDAQ;GERN), Advanced Cell Technology (OTC:ACTC), International Stem Cell Corp. (OTC:ISCO), Pluristem Therapeutics ...

View the full article